{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:46Z","timestamp":1772166346519,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Although Singapore is one of the highest vaccinated countries in the world, vaccine hesitancy remains in a subpopulation, including individuals with cancer predisposition syndromes. At the Cancer Genetics Service National Cancer Centre Singapore, we see patients with germline genetic alterations, most being\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      pathogenic\/likely pathogenic variant (PV\/LPV) carriers. While reported safe for cancer patients, there are limited studies addressing the safety profile and outcomes of COVID-19 vaccination among individuals with germline PV\/LPV in cancer predisposition genes such as\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      . This study aims to evaluate the outcomes of COVID-19 vaccination among germline PV\/LPV carriers in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a phone call survey of COVID-19 vaccination uptake and toxicity in a prospective cohort of 189 participants with germline\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      PV\/LPV between 1st Sept 2021 and 30th Sept 2021. We collected demographics data including gender, race, age, history of cancer, types of cancer, and number of cancers. Statistical difference in baseline demographics between responders with history of cancer and those without were assessed using Chi-square, Fisher\u2019s exact and independent t-test analysis. Logistic regression was used to evaluate effect of demographics on the occurrence of post-vaccination side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 189\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      PV\/LPV carriers responded, 97 carried PV\/LPV in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and 92 in\n                      <jats:italic>BRCA2<\/jats:italic>\n                      . Majority were vaccinated (89.5%) and had completed the two-dose vaccine schedule, with 7 (4.1%) received only one dose. The most common post-vaccination side effects was myalgia (56.5%) followed by fever (40.2%), headache (16.3%) and fatigue (11.2%). There were no major severe side events. Evaluation by logistic regression showed that the occurrence of side effects was not affected by PV\/LPV gene (\n                      <jats:italic>BRCA1<\/jats:italic>\n                      or\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ), gender, race, age or history of cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The post-vaccination side effects profile among individuals with germline PV\/LPV in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      is consistent with the Singaporean general population, hence recommendations for COVID-19 vaccination for these individuals should not differ from non-carriers and should be encouraged by their healthcare providers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-023-00248-2","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T08:02:59Z","timestamp":1681286579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore"],"prefix":"10.1186","volume":"21","author":[{"given":"Zewen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Diana Binte","family":"Ishak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances Victoria Fajardo","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi Yang","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sock Hoai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne Ngeow Yuen","family":"Yie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"248_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2020.04.004","volume":"132","author":"A Leonetti","year":"2020","unstructured":"Leonetti A, Facchinetti F, Zielli T, Brianti E, Tiseo M. COVID-19 in lung cancer patients receiving ALK\/ROS1 inhibitors. Eur J Cancer. 2020;132:122\u20134.","journal-title":"Eur J Cancer"},{"key":"248_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","volume":"100","author":"MM R\u00fcthrich","year":"2021","unstructured":"R\u00fcthrich MM, et al. COVID-19 in cancer patients: clinical characteristics and outcome\u2014an analysis of the LEOSS registry. Ann Hematol. 2021;100:383\u201393.","journal-title":"Ann Hematol"},{"key":"248_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10549-020-05667-6","volume":"182","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in new York City. Breast Cancer Res Treat. 2020;182:239\u201342.","journal-title":"Breast Cancer Res Treat"},{"key":"248_CR4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907\u201318.","journal-title":"Lancet"},{"key":"248_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914\u201322.","journal-title":"Lancet Oncol"},{"key":"248_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","volume":"23","author":"MS Diamond","year":"2022","unstructured":"Diamond MS, Kanneganti T-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022;23:165\u201376.","journal-title":"Nat Immunol"},{"key":"248_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861\u201380.","journal-title":"Cell"},{"key":"248_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2249.2000.01257.x","volume":"121","author":"AR Gennery","year":"2001","unstructured":"Gennery AR, Cant AJ, Jeggo PA. Immunodeficiency associated with DNA repair defects. Clin Exp Immunol. 2001;121:1\u20137.","journal-title":"Clin Exp Immunol"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMra0802968","volume":"359","author":"WD Foulkes","year":"2008","unstructured":"Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143\u201353.","journal-title":"N Engl J Med"},{"key":"248_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/ajh.24046","volume":"90","author":"N Giri","year":"2015","unstructured":"Giri N, et al. Immune status of patients with inherited bone marrow failure syndromes: immune function in IBMFS. Am J Hematol. 2015;90:702\u20138.","journal-title":"Am J Hematol"},{"key":"248_CR11","doi-asserted-by":"publisher","first-page":"e26599","DOI":"10.1002\/pbc.26599","volume":"64","author":"KC Myers","year":"2017","unstructured":"Myers KC, et al. Impaired immune function in children and adults with Fanconi anemia. Pediatr Blood Cancer. 2017;64:e26599.","journal-title":"Pediatr Blood Cancer"},{"key":"248_CR12","first-page":"297","volume":"84","author":"AR Marra","year":"2022","unstructured":"Marra AR, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. J Inf Secur. 2022;84:297\u2013310.","journal-title":"J Inf Secur"},{"key":"248_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccell.2021.12.002","volume":"40","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;40:103\u2013108.e2.","journal-title":"Cancer Cell"},{"issue":"175","key":"248_CR14","first-page":"1","volume":"1990","author":"LYW Lee","year":"2022","unstructured":"Lee LYW, et al. COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study. Eur J Cancer Oxf Engl. 2022;1990(175):1\u201310.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"248_CR15","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22:1681\u201391.","journal-title":"Lancet Oncol"},{"key":"248_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581\u20133.","journal-title":"Lancet Oncol"},{"key":"248_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378.","journal-title":"Lancet Oncol"},{"key":"248_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.21.01891","volume":"40","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, et al. Immunogenicity and Reactogenicity of SARS-CoV-2 vaccines in patients with Cancer: the CANVAX cohort study. J Clin Oncol. 2022;40:12\u201323.","journal-title":"J Clin Oncol"},{"key":"248_CR19","unstructured":"Ministry of Health, S. COVID-19 Vaccination Frequently Asked Questions. https:\/\/www.vaccine.gov.sg\/faq."},{"key":"248_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5:947\u201353.","journal-title":"Nat Hum Behav"},{"key":"248_CR21","unstructured":"Singapore Cancer Society. COVID-19 Vaccines and Cancer. https:\/\/www.singaporecancersociety.org.sg\/covid-19.html."},{"key":"248_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-018-4098-y","volume":"18","author":"M Ibrahim","year":"2018","unstructured":"Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18:179.","journal-title":"BMC Cancer"},{"key":"248_CR23","unstructured":"Centre for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/pfizer\/reactogenicity.html."},{"key":"248_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.47102\/annals-acadmedsg.2021160","volume":"50","author":"SM Lim","year":"2021","unstructured":"Lim SM, et al. Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination amonghealthcare workers: a tertiary hospital experience in Singapore. Ann Acad Med Singap. 2021;50:703\u201311.","journal-title":"Ann Acad Med Singap"},{"key":"248_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.033","volume":"159","author":"E Garreffa","year":"2021","unstructured":"Garreffa E, et al. Regional lymphadenopathy following COVID-19 vaccination: literature review and considerations for patient management in breast cancer care. Eur J Cancer. 2021;159:38\u201351.","journal-title":"Eur J Cancer"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-023-00248-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T08:11:58Z","timestamp":1681287118000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-023-00248-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1186\/s13053-023-00248-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1749535\/v1","asserted-by":"object"}]},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the SingHealth Centralised Institutional Review Board (IRB: 2021\u20132593).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Joanne Ngeow receives research funding from Astra Zeneca for research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}